From the Department of Pediatric Gastroenterology, Hepatology and Nutrition, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Exp Clin Transplant. 2022 May;20(Suppl 3):102-104. doi: 10.6002/ect.PediatricSymp2022.O33.
Immunosuppressive therapy is a double-edged sword and causes a risk for some complications, such as opportunistic infections and posttransplant lymphoproliferative disease. The most likely risk factors for posttransplant lymphoproliferative disease are Epstein-Barr virus serology mismatch, prolonged and high viral load for Epstein-Barr virus, higher doses of immunosuppressive therapy, and cytomegalovirus infection. Transplant recipients who are seropositive for Epstein-Barr virus show a lower risk for posttransplant lymphoproliferative disease than seronegative recipients. Here, we present a 3.5-year-old boy who was seropositive for Epstein-Barr virus and developed posttransplant lymphoproliferative disease 18 months after liver transplant with a previous history of cytomegalovirus- related pneumatosis intestinalis.
免疫抑制疗法是一把双刃剑，会导致一些并发症的风险，如机会性感染和移植后淋巴组织增生性疾病。移植后淋巴组织增生性疾病最可能的危险因素是 EBV 血清学不匹配、EBV 病毒载量持续高、免疫抑制治疗剂量高和巨细胞病毒感染。 EBV 血清学阳性的移植受者发生移植后淋巴组织增生性疾病的风险低于 EBV 血清学阴性的受者。在此，我们报告了一例 3.5 岁男孩，他在肝移植后 18 个月发生了 EBV 相关的移植后淋巴组织增生性疾病，该男孩在肝移植前曾有巨细胞病毒相关的肠气肿病史，并且 EBV 血清学呈阳性。
